This meta-analysis from 2022, evaluates the efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of type 1 diabetes. It summarizes the findings from multiple clinical trials and provides a comprehensive assessment of the potential benefits and risks of MSC therapy.
Menu
